Images (click to zoom)
||Beta-synuclein is a non-amyloid component of senile plaques found in Alzheimer disease. It could act as a regulator of SNCA aggregation. It protects neurons from staurosporine and 6 hydroxy dopamine -stimulated capspase activation in a p53-dependent manner. It localises to the cytoplasm and it is predominantly expressed in the brain where it is most concentrated in presynaptic nerve terminals. This protein is phosphorylated. This protein is also associated with the disease Brain iron accumulation type 1 (NBIA1).
||See product label
||A synthetic peptide (IEPLMEPEGSYEDPPQE) of human beta synuclein protein (aa: 108-125) conjugated to diptheria toxid has been used as the immunogen.
|| Q16143 SYUB_HUMAN;
||IHC. A working concentration of 1 ug/mL is recommended. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
||Known to be specific for beta synuclein.
||This antiserum is known to react with beta synuclein of human, rat and other rodents.
||If you would like to use this product in another species other than those specified here, or to see the shared identity between the immunogen used here in different speices and/or other molecules, simply copy the immunogen (from the Immunogen field) and paste it HERE and blast/format it. Note that, antisera raised against synthetic peptides are quite often very specific for that peptide ie, only one single amino acid difference may be enough to restrict the specificity to a particular molecule. Regardless, you can always contact us if you need assistance with this.
||Affinity purified and dialysed against PBS. Contains 0.02% sodium azide.
||Reconstitute in 100 uL of sterile water. Centrifuge to remove any insoluble material.
||After reconstitution keep aliquots at -20C for a higher stability, and at 2-8C with an appropriate antibacterial agent. Glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles.
||12 months after purchase
||1. Lundvig, et al Brain Res Mol Brain Res 134, 3-17 (Mar 24, 2005).
2. Bennett, Pharmacol Ther 105, 311-31 (Mar, 2005).
3. Vekrellis, et al., Mol Neurobiol 30, 1-21 (Aug, 2004).
4. Martin, et al., Protein Pept Lett 11, 229-37 (Jun, 2004).
5. Doherty, et al., Acta Neuropathol (Berl) 107, 169-75 (Feb, 2004).
6. Goedert, Curr Opin Genet Dev 11, 343-51 (Jun, 2001).
7. Saito, et al., J Neurol Sci 177, 48-59 (Aug 1, 2000).
8. Lucking et al. Cell Mol Life Sci. 2000 Dec;57(13-14):1894-908.
9. Kahle, et al., Ann N Y Acad Sci 920, 33-41 (2000).
10. Clayton, et al., Trends Neurosci 21, 249-54 (Jun, 1998).
||Immunohistochemical staining of beta synuclein in rat spinal cord using sheep polyclonal to human beta synuclein, catalogue number S-077-100